
EquityIndex FundsVery High Risk
Regular
NAV (10-Dec-25)
Returns (Since Inception)
Fund Size
₹29 Cr
Expense Ratio
1.11%
ISIN
INF247L01DT9
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
19 Nov 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-1.37%
— (Cat Avg.)
Since Inception
+3.62%
— (Cat Avg.)
| Equity | ₹29.37 Cr | 99.84% |
| Others | ₹0.05 Cr | 0.16% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Lupin Ltd | Equity | ₹2.75 Cr | 9.33% |
| Fortis Healthcare Ltd | Equity | ₹2.61 Cr | 8.87% |
| Laurus Labs Ltd | Equity | ₹2.19 Cr | 7.43% |
| Aurobindo Pharma Ltd | Equity | ₹1.87 Cr | 6.36% |
| Alkem Laboratories Ltd | Equity | ₹1.75 Cr | 5.94% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹1.6 Cr | 5.43% |
| Mankind Pharma Ltd | Equity | ₹1.39 Cr | 4.72% |
| Biocon Ltd | Equity | ₹1.31 Cr | 4.44% |
| Ipca Laboratories Ltd | Equity | ₹1.1 Cr | 3.75% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.92 Cr | 3.13% |
| Abbott India Ltd | Equity | ₹0.85 Cr | 2.90% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.82 Cr | 2.79% |
| Neuland Laboratories Ltd | Equity | ₹0.81 Cr | 2.75% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.79 Cr | 2.67% |
| Gland Pharma Ltd | Equity | ₹0.76 Cr | 2.60% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.72 Cr | 2.45% |
| Syngene International Ltd | Equity | ₹0.67 Cr | 2.28% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.64 Cr | 2.16% |
| Piramal Pharma Ltd | Equity | ₹0.63 Cr | 2.14% |
| Ajanta Pharma Ltd | Equity | ₹0.59 Cr | 2.00% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.58 Cr | 1.97% |
| Global Health Ltd | Equity | ₹0.57 Cr | 1.95% |
| Wockhardt Ltd | Equity | ₹0.56 Cr | 1.89% |
| OneSource Specialty Pharma Ltd | Equity | ₹0.46 Cr | 1.57% |
| Granules India Ltd | Equity | ₹0.44 Cr | 1.50% |
| Natco Pharma Ltd | Equity | ₹0.43 Cr | 1.46% |
| Pfizer Ltd | Equity | ₹0.41 Cr | 1.40% |
| Poly Medicure Ltd | Equity | ₹0.4 Cr | 1.37% |
| Cohance Lifesciences Ltd | Equity | ₹0.39 Cr | 1.34% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.37 Cr | 1.25% |
| Net Receivables / (Payables) | Cash | ₹0.05 Cr | 0.16% |
Large Cap Stocks
14.05%
Mid Cap Stocks
53.50%
Small Cap Stocks
32.30%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹29.37 Cr | 99.84% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since November 2024

Since November 2024
Since December 2024
ISIN INF247L01DT9 | Expense Ratio 1.11% | Exit Load 1.00% | Fund Size ₹29 Cr | Age 1 year | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark Nifty MidSmall Healthcare Index (TRI) |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹1,43,075 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Your principal amount will be at Very High Risk


EquityIndex FundsVery High Risk
Regular
NAV (10-Dec-25)
Returns (Since Inception)
Fund Size
₹29 Cr
Expense Ratio
1.11%
ISIN
INF247L01DT9
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
19 Nov 2024
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-1.37%
— (Cat Avg.)
Since Inception
+3.62%
— (Cat Avg.)
| Equity | ₹29.37 Cr | 99.84% |
| Others | ₹0.05 Cr | 0.16% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Lupin Ltd | Equity | ₹2.75 Cr | 9.33% |
| Fortis Healthcare Ltd | Equity | ₹2.61 Cr | 8.87% |
| Laurus Labs Ltd | Equity | ₹2.19 Cr | 7.43% |
| Aurobindo Pharma Ltd | Equity | ₹1.87 Cr | 6.36% |
| Alkem Laboratories Ltd | Equity | ₹1.75 Cr | 5.94% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹1.6 Cr | 5.43% |
| Mankind Pharma Ltd | Equity | ₹1.39 Cr | 4.72% |
| Biocon Ltd | Equity | ₹1.31 Cr | 4.44% |
| Ipca Laboratories Ltd | Equity | ₹1.1 Cr | 3.75% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.92 Cr | 3.13% |
| Abbott India Ltd | Equity | ₹0.85 Cr | 2.90% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.82 Cr | 2.79% |
| Neuland Laboratories Ltd | Equity | ₹0.81 Cr | 2.75% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.79 Cr | 2.67% |
| Gland Pharma Ltd | Equity | ₹0.76 Cr | 2.60% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.72 Cr | 2.45% |
| Syngene International Ltd | Equity | ₹0.67 Cr | 2.28% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.64 Cr | 2.16% |
| Piramal Pharma Ltd | Equity | ₹0.63 Cr | 2.14% |
| Ajanta Pharma Ltd | Equity | ₹0.59 Cr | 2.00% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.58 Cr | 1.97% |
| Global Health Ltd | Equity | ₹0.57 Cr | 1.95% |
| Wockhardt Ltd | Equity | ₹0.56 Cr | 1.89% |
| OneSource Specialty Pharma Ltd | Equity | ₹0.46 Cr | 1.57% |
| Granules India Ltd | Equity | ₹0.44 Cr | 1.50% |
| Natco Pharma Ltd | Equity | ₹0.43 Cr | 1.46% |
| Pfizer Ltd | Equity | ₹0.41 Cr | 1.40% |
| Poly Medicure Ltd | Equity | ₹0.4 Cr | 1.37% |
| Cohance Lifesciences Ltd | Equity | ₹0.39 Cr | 1.34% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.37 Cr | 1.25% |
| Net Receivables / (Payables) | Cash | ₹0.05 Cr | 0.16% |
Large Cap Stocks
14.05%
Mid Cap Stocks
53.50%
Small Cap Stocks
32.30%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹29.37 Cr | 99.84% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since November 2024

Since November 2024
Since December 2024
ISIN INF247L01DT9 | Expense Ratio 1.11% | Exit Load 1.00% | Fund Size ₹29 Cr | Age 1 year | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark Nifty MidSmall Healthcare Index (TRI) |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹1,43,075 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments